Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer

BACKGROUND: Nonpegylated liposomal doxorubicin liposomal doxorubicin, (Myocet™; Sopherion Therapeutics, Inc Canada, and Cephalon, Europe) (NPLD; Myocet(®)) in combination with trastuzumabHerceptin(®) (Hoffmann-La Roche) has shown promising activity and cardiac safety. We conducted a randomized phase...

全面介紹

Na minha lista:
書目詳細資料
發表在:Ann Oncol
Main Authors: Baselga, J., Manikhas, A., Cortés, J., Llombart, A., Roman, L., Semiglazov, V. F., Byakhov, M., Lokanatha, D., Forenza, S., Goldfarb, R. H., Matera, J., Azarnia, N., Hudis, C. A., Rozencweig, M.
格式: Artigo
語言:Inglês
出版: Oxford University Press 2014
主題:
Original Articles
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4433508/
https://ncbi.nlm.nih.gov/pubmed/24401928
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt543
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍